Medicon Valley Alliance and Celerion would like to welcome you to a Good Morning Meeting 12th of November 2026.
With industry estimating a cost of ~$2bn to bring a new drug to market and Phase 2 representing the main valley of death in clinical development with a ~70% failure rate, it has never been more important for Sponsors to do all they can to de-risk the development of their drug candidates at that translational inflection point.
Ensuring assay robustness, taking advantage of the latest lab automation technologies, designing your First-in-Human clinical study to maximise value and choosing the right partners for your development plan to deliver high-quality data on time and within budget are all critical elements of de-risking and setting up for success.
Join the Celerion team to hear about this and more based on their 50 years’ experience in translational drug development.
Date: Thursday 12th of November 2026
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Hub2 Auditorium
Program
| 8:30 | Networking, registration and light breakfast |
| 9:00 | Welcome and introduction to Medicon Valley Alliance David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
| 9:05 | Introduction of speakers Nathan McCavery, Senior Director, Business Development, Celerion |
| 9:10 | Setting up for bioanalytical success Petra Struwe, Vice President, Bioanalytical Services, Celerion |
| 9:25 | Delivering Bioanalytical Data Faster, Smarter, Better Wibke Lembke, Senior Director, Ligand Binding Services and Molecular & Cellular Biology |
| 9:40 | Assay Optimisation & Lifecycle Management Gabriele Conti, Senior Bioanalytical Principal Investigator, Celerion |
| 9:55 | Recent Trends Shaping First-in-Human Study Designs Aernout van Haarst, Senior Director, Scientific Affairs, Celerion |
| 10:10 | Q&A / Discussion |
| 10:30 | Networking |
| 11:00 | End of Good Morning Meeting |
Speakers
 |
Petra Struwe, Ph.D., Vice President, Bioanalytical Services, Celerion
Petra is Vice President of Bioanalytical Services at the Celerion facility in Zurich and is responsible for the scientific and operational leadership for both small and large molecule bioanalysis. In this role she is responsible for bioanalytical, biomarker and immunogenicity method development, validation and associated sample analysis to support drug discovery, drug development and biosimilar research. Petra holds a PhD in chemistry and before joining Celerion she held various positions with increasing responsibility in federal institutes, Solvay Pharmaceuticals and MDS Pharma Services. She has more than 30 years of industry experience in regulated bioanalysis within the pharmaceutical and CRO industry. |
 |
Wibke Lembke, Ph.D., Senior Director, Ligand Binding Services and Molecular & Cellular Biology, Celerion
Wibke is Senior Director for Ligand Binding and Molecular & Cellular Biology Services at Celerion’s Zurich facility. Wibke has become a recognized bioanalytical and biomarker professional over the last 15+ years actively shaping the bioanalytical landscape by being an active contributor to Europe’s bioanalytical and immunogenicity scientific community. She gained in-depth experience in the drug development of diverse modalities (mAbs, bispecifics, alternative scaffolds, fusion proteins, macrocyclic peptides, small molecules as well as Cell and Gene Therapies) in a variety of different disease indications from discovery to post marketing in both Biotech and Pharma. As part of her previous roles at Covagen, J&J and UCB, Wibke strategically and operationally lead bioanalytical and translational research groups, established bioanalytical and translational biomarker strategies on a portfolio level and worked on CRO outsourcing strategies (oversight, governance, selection, audits and monitoring). |
 |
Gabriele Conti, Ph.D., Senior Bioanalytical Principal Investigator, Celerion
Gabriele Conti, PhD, is a Senior Bioanalytical Principal Investigator at Celerion Switzerland AG. He holds a PhD in Pharmaceutical Sciences from the University of Basel and Utrecht University, and degrees in Chemical Sciences from the University of Milan. Since joining Celerion in 2022, he has supported the development, validation, and application of bioanalytical methods for regulated studies, with a particular focus on ligand-binding assays. Prior to Celerion, his research activities ranged from medicinal chemistry and API production to the discovery and preclinical characterization of novel lectin ligands for infectious disease applications. |
 |
Aernout van Haarst, Ph.D., Director, Scientific Affairs, Celerion
Aernout is Director, Scientific Affairs at Celerion. In this key leadership position, Aernout provides scientific, operational and regulatory support for early phase clinical studies. |
| Organized by | In collaboration with |
 |
 |